Pictet Asset Management Ltd. Has $6.84 Million Stock Holdings in Sangamo Therapeutics Inc (NASDAQ:SGMO)

Pictet Asset Management Ltd. lifted its stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 46.0% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 634,941 shares of the biopharmaceutical company’s stock after buying an additional 200,000 shares during the quarter. Pictet Asset Management Ltd. owned about 0.55% of Sangamo Therapeutics worth $6,838,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Wasatch Advisors Inc. lifted its stake in shares of Sangamo Therapeutics by 2.5% during the 2nd quarter. Wasatch Advisors Inc. now owns 6,598,908 shares of the biopharmaceutical company’s stock worth $71,070,000 after buying an additional 161,000 shares during the last quarter. Northern Trust Corp increased its position in Sangamo Therapeutics by 3.9% during the second quarter. Northern Trust Corp now owns 1,373,469 shares of the biopharmaceutical company’s stock worth $14,793,000 after acquiring an additional 51,137 shares during the period. Dimensional Fund Advisors LP increased its position in Sangamo Therapeutics by 459.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock worth $14,224,000 after acquiring an additional 1,017,573 shares during the period. Wells Fargo & Company MN increased its position in Sangamo Therapeutics by 25.1% during the second quarter. Wells Fargo & Company MN now owns 821,420 shares of the biopharmaceutical company’s stock worth $8,847,000 after acquiring an additional 164,784 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Sangamo Therapeutics by 14.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 676,556 shares of the biopharmaceutical company’s stock worth $7,287,000 after acquiring an additional 86,660 shares during the period. Institutional investors own 69.02% of the company’s stock.

NASDAQ:SGMO traded up $0.24 during mid-day trading on Monday, reaching $11.09. 24,706 shares of the company’s stock were exchanged, compared to its average volume of 973,115. Sangamo Therapeutics Inc has a one year low of $6.26 and a one year high of $17.35. The firm has a market capitalization of $1.29 billion, a PE ratio of -15.81 and a beta of 2.90. The business’s fifty day simple moving average is $11.31 and its two-hundred day simple moving average is $10.72.



Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.09. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. The firm had revenue of $17.55 million for the quarter, compared to analyst estimates of $13.58 million. During the same period last year, the firm earned ($0.17) EPS. The business’s quarterly revenue was down 18.1% compared to the same quarter last year. As a group, analysts expect that Sangamo Therapeutics Inc will post -1.39 earnings per share for the current fiscal year.

A number of research firms recently commented on SGMO. BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Monday, July 8th. ValuEngine raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Zacks Investment Research raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Finally, HC Wainwright began coverage on shares of Sangamo Therapeutics in a research report on Monday, August 26th. They set a “buy” rating and a $16.00 price target on the stock. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $14.00.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

See Also: Is the QQQ ETF safe?

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.